C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/09 (2006.01) A61K 31/713 (2006.01) A61K 48/00 (2006.01) A61P 35/00 (2006.01) C12Q 1/68 (2006.01) G01N 33/15 (2006.01) G01N 33/53 (2006.01)
Patent
CA 2734979
The present invention relates to the roles played by the SYNGR4 genes in lung cancer carcinogenesis and features a method for treating or preventing lung cancer by administering a double- stranded molecule against one or more of the SYNGR4 genes or a composition, vector or cell containing such a double stranded molecule and antibody. The present invention also features methods for diagnosing lung cancer or assessing/determining the prognosis of a patient with lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among SYNGR4. To that end, SYNGR4 may serve as a novel serological biomarker for lung cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of SYNGR4 in the lung cancer.
La présente invention concerne les rôles joués par les gènes SYNGR4 dans la carcinogenèse du cancer du poumon et concerne un procédé de traitement ou de prévention du cancer du poumon par administration dune molécule bicaténaire contre un ou plusieurs des gènes SYNGR4 ou dune composition, dun vecteur ou dune cellule contenant une telle molécule bicaténaire et un anticorps. La présente invention concerne également des procédés de diagnostic du cancer du poumon ou dévaluation/détermination du pronostic dun patient atteint du cancer du poumon, notamment NSCLC ou SCLC, qui utilisent un ou plusieurs gènes surexprimés choisis parmi SYNGR4. A cette fin, SYNGR4 peut servir de nouveau biomarqueur sérologique pour le cancer du poumon. Linvention concerne également des procédés didentification de composés pour traiter et prévenir le cancer du poumon, qui utilisent en tant quindice leur effet sur la surexpression dun ou de plusieurs SYNGR4 dans le cancer du poumon.
Daigo Yataro
Nakamura Yusuke
Togashi Akira
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Oncotherapy Science Inc.
LandOfFree
Syngr4 for target genes of cancer therapy and diagnosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Syngr4 for target genes of cancer therapy and diagnosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Syngr4 for target genes of cancer therapy and diagnosis will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1632647